S&P 500
5.180,74 +52,95 (+1,03%) Nasdaq
16.349,25 +192,92 (+1,19%) NIKKEI 225
38.741,48 +505,41 (+1,32%) Dólar/Euro
1,0777 +0,0003 (+0,03%) Petróleo Brent
83,79 +0,46 (+0,55%) Bitcoin EUR
58.911,56 -694,88 (-1,17%)
Aida Pharmaceuticals, Inc. (AIDA)
Aida Pharmaceuticals, Inc.
31 Dingjiang Road
Jianggan District
Hangzhou 310016
China
86 571 8580 2712
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 450
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Biao Jin | Chairman and Chief Executive Officer | 19,06k | N/A | 1948 |
| Ms. Lin Hui | Chief Financial Officer and Principal Accounting Officer | 12,7k | N/A | 1966 |
| Mr. Yue Jun Jiang | Chief of Investment Department and Secretary | N/A | N/A | 1975 |
| Mr. Qiu Jiajun | Member of Compensation Committee and Director | N/A | N/A | 1966 |
Descripción
Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.
Gobierno corporativo
El ISS Governance QualityScore de Aida Pharmaceuticals, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
